Berzelius symposium 91
31 August–1 September 2016 at Hotel Skansen in Båstad, Sweden
Purpose statement: CVD and type 2 diabetes are devastating and costly diseases whose prevalence is increasing rapidly around the world, projected to exceed billions of people worldwide within the next decades. Although drug and lifestyle interventions are used widely to prevent and treat CVD and diabetes, neither is highly effective; for example, in high risk adults, intensive lifestyle intervention delays the onset of disease by roughly 3-years and with metformin by 18-months compared to placebo control intervention (Knowler et al, Lancet, 2009), with diabetes “prevention” being the exception, rather than the rule.
Moreover, whilst some patients respond very well to therapies, others benefit little or not at all, progressing rapidly through the pre-diabetic phase of beta-cell decline and later developing life-threatening complications such as retinopathy, nephropathy, peripheral neuropathy, and cardiovascular disease. As such, there is an urgent need to develop innovative and effective prevention and treatment strategies. Human biology is complex and people differ in their genetic and molecular characteristics, which underlies the variable response to interventions and rates of disease progression. Thus, a huge, as yet unrealised opportunity exists to optimize the prevention and treatment of CVD and type 2 diabetes by tailoring therapies to the patient’s unique biology. This concept is often termed “precision medicine”. This conference will bring together thought-leaders in diabetes precision medicine who will present the state-of-the-science and discuss future prospects.
Participants: The conference is open to all active scientists working in the field, but we will seek to ensure an even gender and career stage distribution amongst attendees by advertising more intensively to underrepresented delegate groups.
The symposium is endorsed by the Swedish Society of Medicine and supported by the Swedish Research Council (Vetenskapsrådet), Hjärt Lungfonden, EpiHealth, Eli Lilly, Sanofi Aventis, Novo Nordisk, Exodiab
Organizer: Paul Franks, firstname.lastname@example.org
Tuesday, August 30th
Registration for delegates start at 4 pm.
Wednesday, August 31st
09.00-09.15 Welcome and introduction.
Paul Franks, Lund University Diabetes Center, Sweden
09.15-10.00 Precision medicine: where are we and where are we going?
Leif Groop, Lund University Diabetes Center, Sweden
10.00-10.45 What industry wants from academic partnerships in precision medicine.
Hartmut Ruetten, Sanofi, Germany
10.45-11.15 Coffee break (poster session 1)
11.15-12.15 Why national initiatives and global collaborations are needed and how they are taking shape. Phil Smith, NIDDK, US
13.30-14.15 The genetics of therapeutic response. Jose Florez, Harvard, US
14.15-15.00 Is genotype-guided lifestyle therapy on the horizon?
Anna Krook, Karolinska Institutet, Sweden
15.00-15.30 Coffee break (poster session 2)
15.30-16.15 A translational approach to resolve T2D pathogenesis.
Hindrik Mulder, Lund University
16.15-17.00 Functional genomics. Manolis Kellis, MIT, US
17.00-17.45 Elucidating mechanisms. Anna Gloyn, Oxford, UK
19.00-22.00 Symposium dinner
Thursday, September 1st
09.00-09.45 What can monogenic obesity teach us about disease stratification and personalized treatment in type 2 diabetes? Giles Yeo, Cambridge, UK
09.45-10.30 What can monogenic diabetes teach us about disease stratification and personalized treatment in type 2 diabetes? Andrew Hattersley, Exeter, UK
10.30-11.15 Making precision medicine personal. Mike Snyder, Stanford, US
11.15-12.00 Commercialization of precision medicine. Adam Auton, 23andMe, US
13.00-14.00 Debate: precision medicine will transform patient care for the better:
for: Ewan Pearson, University of Dundee, UK
against: Simon Griffin, University of Cambridge, UK
14.00-14.45 Nature genetics' view of the prospects for precision medicine.
Myles Axton, Cheif Editor, Nature Genetics
14.45-15.00 Coffee break (poster session 3)
15.00-15.45 Innovation in big data analysis. Mark McCarthy, Oxford, UK
15.45-16.00 Closing remarks. Paul Franks
More information: email@example.com